Predictors of Discharge From the VA Caregiver Support Program
The year of application predicts discharge from the Department of Veterans Affairs (VA) caregiver program. Unexpected, disallowed criteria also predict discharge, with significant others facing higher discharge risk than spouses.
Collaborative Care Implementation: Lessons Learned
The authors drafted a “Shared Values of Collaborative Care” document with fundamental principles to make better group decisions in implementing collaborative care.
Premium Tax Credits in the American Rescue Plan and Off-Marketplace Enrollees
We estimate that the median 2021 premium tax credit for off-marketplace enrollees in California would be $311 if they switched to marketplace plans, with wide variation by age and plan size.
Activation, Physical Activity, and Outcomes Among Individuals With T2D
This study presents an integrated, exploratory assessment of physical activity, patient activation, health-related quality of life, and clinical outcomes among older adults with type 2 diabetes (T2D) using survey, wellness, and claims data.
Preappointment Surveys and Reminder Calls to Improve Show Rate
Patients who completed a preappointment survey were significantly more likely to attend their clinic appointment than noncompleters and spent significantly less time in their appointment.
Value-Based Payment, the Safety Net, and Rethinking Risk
August 2nd 2022Safety-net providers can benefit from demonstrations of condition-specific and defined-scope-of-practice alternative payment models that account for the nonfinancial as well as financial risks that providers face.
Glucose-Lowering Treatment Patterns in Patients With Diabetic Kidney Disease
Real-world treatment of diabetic kidney disease in the United States, based on national-level health care claims and electronic health records data, is inconsistent with the current guidelines.
Coverage With Evidence Development: Where Are We Now?
Review of CMS’ coverage with evidence development program exposes a need to improve program transparency and clarify requirements and timetables for reporting to improve access to novel therapies.